Search Results

You are looking at 1 - 10 of 48 items for :

  • All content x
Clear All
Hungarian Medical Journal
Authors: Miklós Egyed, Balázs Kollár, Péter Rajnics, Éva Karádi, and András Matolcsi

Colombat, M., Fort, M. P., Chollet, C. et al.: Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment

Restricted access
Orvosi Hetilap
Authors: Miklós Egyed, Balázs Kollár, Péter Rajnics, Éva Karádi, and András Matolcsi

Colombat, M., Fort, M. P., Chollet, C. és mtsai: Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment

Restricted access

M, Amoroso S, di Renzo G, Annunziato L: Imatinib-mesylate blocks recombinant T-type calcium channels expressed in human embryonic kidney-293 cells by a protein tyrosine kinase-independent mechanism. J. Pharmacol. Exp. Ther. 309, 208–215 (2004

Restricted access
Orvosi Hetilap
Authors: Gyöngyi Kirschner, Bernadett Balla, János Kósa, Péter Horváth, Andrea Kövesdi, Gergely Lakatos, István Takács, Zsolt Nagy, Bálint Tóbiás, Kristóf Árvai, and Péter Lakatos

regulatory mechanisms, accelerated approval, and orphan drug status. Oncologist, 2002, 7 (5), 390–392. 2 Jönsson, S., Hjorth-Hansen, H., Olsson, B., et al.: Imatinib

Open access
Journal of Thermal Analysis and Calorimetry
Authors: M. Łaszcz, B. Kosmacińska, K. Korczak, B. Śmigielska, M. Glice, W. Maruszak, A. Groman, H. Beczkowicz, and Ł. Żelazko

Abstract  

Differential scanning calorimetry and thermogravimetric analysis with the support of X-ray powder diffraction and infrared spectroscopy were used as screening techniques for the compatibility testing of imatinib mesylate, with following excipients: magnesium stearate, polyvinylpyrrolidone, microcrystalline cellulose. In order to maximize the probability of interactions 1:1 (by mass) drug: excipient binary mixtures were analysed and compared to individual components. Additionally an influence of storage at temperatures of 25 and 40°C on physico-chemical stability on drug – excipient binary mixtures was investigated. The largest visible changes were observed in the DSC curves of imatinib mesylate – magnesium stearate mixtures.

Restricted access

Lee, J. L., Kim, J. Y., Ryu, M. H. és mtsai: Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1. Dig. Dis. Sci., 2006, 51 , 1043–1046. Ryu

Restricted access

– 232 . [31]. J. L. Lee J. Y. Kim M. H. Ryu 2006 Response to imatinib in KIT-and PDGFRA-wild type gastrointestinal stromal associated with Neurofibromatosis type 1 Dig. Dis. Sci. 51 1043 – 1046 . [32]. J. Lasota M

Restricted access
Magyar Sebészet
Authors: Jassó András, Bertha László, Gyökeres Tibor, Takács Imre Géza, and Bursics Attila

Antonescu , P Besmer , T Guo , K Arkun , G Hom , B Koryotowski , MA Leversha , PD Jeffrey , D Desantis , S Singer , MF Brennan , RG Maki , RP DeMatteo : 2005 Acquired resistance to imatinib in gastrointestinal stromal tumor occurs

Restricted access
Orvosi Hetilap
Authors: Zoltán Mátrai, Gabriella Liszkay, Vanda Plotár, Zsolt Orosz, Judit Székely, Erika Hitre, Alexandra Bartal, Zoltán Langmár, Katalin Bőcs, Ferenc Rényi Vámos, Ákos Sávolt, and László Tóth

McArthur, G. A., Demetri, G. D., van Oosterom, A. és mtsai: Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J. Clin. Oncol., 2005, 23 , 866

Open access
Orvosi Hetilap
Authors: Aliz-Beáta Tunyogi, Erzsébet Lázár, István Benedek jr., Johanna Sándor-Kéri, Annamária Zsigmond, and István Benedek

Deininger MW. Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program 2008; 1: 419–426. 7 Hughes T, Deininger M, Hochhaus A, et al

Restricted access